In representing the pharmaceutical industry in the UK, we work across a range of disciplines and with a diverse set of stakeholders.
Led by our Government Affairs team, we work closely with national, European, devolved and local governments on a range of policy areas.
Following Britain's vote to leave the European Union, we have worked across industry to advise the Government on how Brexit will influence the future of Life Sciences in the UK. At the same time, we continue our existing cross-party policy and parliamentary work, as well as engaging in broad areas such as the development of a new Industrial Strategy.
To influence and inform debate at the 2017 General Election, we have also produced our own manifesto and will analyse the manifesto commitments made by the main political parties.
We work in partnership with the NHS, the Department of Health, NICE and other health bodies to make sure that patients in the UK have access to the very best of modern medicine.
Working across all areas of value and access, this work also includes the Medicines pricing and the supply chain (including the Pharmaceutical Price Regulation Scheme), the Cancer Drugs Fund (CDF), the Falsified Medicine Directive (FMD), the NICE Implementation Collaborative (NIC) and many other specific policy areas.
Our Patient Organisation Forum promotes shared understanding and joint working between patient groups and the pharmaceutical industry.
Our daily work with members allows us to produce detailed publications and guidance about key issues influencing the pharmaceutical industry. We also host the annual ABPI Conference and regular events as forums for discussion and debate.
We also seek to represent the voice of medicines manufacturers in the UK through joint work on the Medicines Manufacturing Industry Partnership. Our member-led Vaccine Group advocates all aspects of vaccination and the benefits it brings to the health of our nation.
Our work across the research, medical and innovation communities tracks the development of a medicine from when a molecule is first identified through to licensing for normal clinical practice.
We also work with our members to take a view on scientific developments in medicine, such as the development of Biological Medicines.
Through up-to-date industry information, the resources we offer for school students and teachers, detailed careers advice, and public campaigns on issues like International Women's Day, we aim to improve public knowledge and understanding of the pharmaceutical industry in the UK.
Disclosure UK is also the industry's commitment to transparency, with our database making publicly available details of certain payments made to healthcare professionals by the pharmaceutical industry.